Log in

Relevant bibliographies by topics / Progressive supranuclear palsy / Journal articles

Journal articles on the topic 'Progressive supranuclear palsy'

To see the other types of publications on this topic, follow the link: Progressive supranuclear palsy.

Author: Grafiati

Published: 4 June 2021

Last updated: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Progressive supranuclear palsy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bartošová, Tereza, and Jiří Klempíř. "Progressive supranuclear palsy." Česká a slovenská neurologie a neurochirurgie 83/116, no. 6 (December 31, 2020): 584–601. http://dx.doi.org/10.48095/cccsnn2020584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rajput, Alex, and Ali H. Rajput. "Progressive Supranuclear Palsy." Drugs & Aging 18, no. 12 (2001): 913–25. http://dx.doi.org/10.2165/00002512-200118120-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fedorova, N. V., E. V. Bril, T. K. Kulua, and A. D. Mikhaylova. "Progressive supranuclear palsy." Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121, no. 5 (2021): 111. http://dx.doi.org/10.17116/jnevro2021121051111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Golbe, Lawrence. "Progressive Supranuclear Palsy." Seminars in Neurology 34, no. 02 (June 25, 2014): 151–59. http://dx.doi.org/10.1055/s-0034-1381736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Karceski, S. "Progressive supranuclear palsy." Neurology 71, no. 22 (November 24, 2008): e70-e72. http://dx.doi.org/10.1212/01.wnl.0000338599.69090.fb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

LEECH, EDWARD E. "Progressive Supranuclear Palsy." American Journal of Nursing 99, no. 6 (June 1999): 24BBBB. http://dx.doi.org/10.1097/00000446-199906000-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pourfar, M. "Progressive Supranuclear Palsy." Science of Aging Knowledge Environment 2004, no. 30 (July 28, 2004): dn1. http://dx.doi.org/10.1126/sageke.2004.30.dn1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Litvan, Irene. "PROGRESSIVE SUPRANUCLEAR PALSY." Neurologist 4, no. 1 (January 1998): 13–20. http://dx.doi.org/10.1097/00127893-199801000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kernich, Catherine Ann. "PROGRESSIVE SUPRANUCLEAR PALSY." Neurologist 5, no. 4 (July 1999): 229. http://dx.doi.org/10.1097/00127893-199907000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Jankovic, Joseph, and Haydee Rohaidy. "Progressive Supranuclear Palsy." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 14, S3 (August 1987): 547–54. http://dx.doi.org/10.1017/s0317167100038099.

Full text

Abstract:

ABSTRACT:Progressive supranuclear palsy (PSP) was first recognized as a distinct morbid entity by Richardson, Steele and Olszewski a quarter century ago. Subsequent experience has confirmed and extended their original observations. PSP has become familiar as a chronic progressive disorder with extrapyramidal rigidity, bradykinesia, gait impairment, bulbar palsy, dementia and a characteristic supranuclear ophthalmoplegia. It is an important cause of parkinsonism. Its etiology remains obscure. Familial concentrations have not been observed.Some cases exhibit no oculomotor dysfunction. Dementia is usually mild. Recent neuropsychological studies have defined features consistent with frontal lobe cortical dysfunction. Seizures and paroxysmal EEG activity may occur.CT and MRI scans show midbrain atrophy early and later atrophy of the pontine and midbrain tegmentum and the frontal and temporal lobes. PET scans have shown frontal hypometabolism and loss of striatal D-2 dopamine receptors. Postmortem studies have documented involvment of both dopaminergic and cholinergic systems. Treatment remains palliative and unsatisfactory.

APA, Harvard, Vancouver, ISO, and other styles

11

Pahwa, Rajesh. "PROGRESSIVE SUPRANUCLEAR PALSY." Medical Clinics of North America 83, no. 2 (March 1999): 369–79. http://dx.doi.org/10.1016/s0025-7125(05)70109-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Boeve, Bradley F. "Progressive supranuclear palsy." Parkinsonism & Related Disorders 18 (January 2012): S192—S194. http://dx.doi.org/10.1016/s1353-8020(11)70060-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lowrey, Becky R., and Lyndon Wong. "Progressive supranuclear palsy." Clinical Eye and Vision Care 12, no. 3-4 (December 2000): 171–75. http://dx.doi.org/10.1016/s0953-4431(00)00055-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kent, Anna. "Progressive supranuclear palsy." Nursing Standard 27, no. 51 (August 21, 2013): 48–57. http://dx.doi.org/10.7748/ns2013.08.27.51.48.e7588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Leech, Edward E. "Progressive Supranuclear Palsy." American Journal of Nursing 99, no. 6 (June 1999): 2401BB. http://dx.doi.org/10.2307/3472143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Mazorra, Loretta, and Mary P. Cadogan. "Progressive Supranuclear Palsy." Journal of Gerontological Nursing 38, no. 3 (February 15, 2012): 8–11. http://dx.doi.org/10.3928/00989134-20120207-07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Lubarsky, Michael, and Jorge L. Juncos. "Progressive Supranuclear Palsy." Neurologist 14, no. 2 (March 2008): 79–88. http://dx.doi.org/10.1097/nrl.0b013e31815cffc9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Amar, Khaled. "Progressive supranuclear palsy." Hospital Medicine 64, no. 10 (October 2003): 585–88. http://dx.doi.org/10.12968/hosp.2003.64.10.2321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rehman, H. U. "Progressive supranuclear palsy." Postgraduate Medical Journal 76, no. 896 (June 1, 2000): 333–36. http://dx.doi.org/10.1136/pmj.76.896.333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ghosh, Boyd CP. "Progressive supranuclear palsy." British Journal of Neuroscience Nursing 10, no. 2 (April 2, 2014): 64–66. http://dx.doi.org/10.12968/bjnn.2014.10.2.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Reeves, A. G. "Progressive Supranuclear Palsy." Archives of Neurology 52, no. 2 (February 1, 1995): 123–24. http://dx.doi.org/10.1001/archneur.1995.00540260021006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Golbe, Lawrence I. "Progressive supranuclear palsy." Current Treatment Options in Neurology 3, no. 6 (November 2001): 473–77. http://dx.doi.org/10.1007/s11940-001-0010-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Miki, Yasuo, Eiki Tsushima, Sandrine C. Foti, Kate M. Strand, Yasmine T. Asi, Adam Kenji Yamamoto, Conceição Bettencourt, et al. "Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy." Brain 144, no. 4 (April 1, 2021): 1138–51. http://dx.doi.org/10.1093/brain/awab017.

Full text

Abstract:

Abstract We studied a subset of patients with autopsy-confirmed multiple system atrophy who presented a clinical picture that closely resembled either Parkinson’s disease or progressive supranuclear palsy. These mimics are not captured by the current diagnostic criteria for multiple system atrophy. Among 218 autopsy-proven multiple system atrophy cases reviewed, 177 (81.2%) were clinically diagnosed and pathologically confirmed as multiple system atrophy (i.e. typical cases), while the remaining 41 (18.8%) had received an alternative clinical diagnosis, including Parkinson’s disease (i.e. Parkinson’s disease mimics; n = 16) and progressive supranuclear palsy (i.e. progressive supranuclear palsy mimics; n = 17). We also reviewed the clinical records of another 105 patients with pathologically confirmed Parkinson’s disease or progressive supranuclear palsy, who had received a correct final clinical diagnosis (i.e. Parkinson’s disease, n = 35; progressive supranuclear palsy-Richardson syndrome, n = 35; and progressive supranuclear palsy-parkinsonism, n = 35). We investigated 12 red flag features that would support a diagnosis of multiple system atrophy according to the current diagnostic criteria. Compared with typical multiple system atrophy, Parkinson’s disease mimics more frequently had a good levodopa response and visual hallucinations. Vertical gaze palsy and apraxia of eyelid opening were more commonly observed in progressive supranuclear palsy mimics. Multiple logistic regression analysis revealed an increased likelihood of having multiple system atrophy [Parkinson’s disease mimic versus typical Parkinson’s disease, odds ratio (OR): 8.1; progressive supranuclear palsy mimic versus typical progressive supranuclear palsy, OR: 2.3] if a patient developed any one of seven selected red flag features in the first 10 years of disease. Severe autonomic dysfunction (orthostatic hypotension and/or urinary incontinence with the need for a urinary catheter) was more frequent in clinically atypical multiple system atrophy than other parkinsonian disorders (Parkinson’s disease mimic versus typical Parkinson’s disease, OR: 4.1; progressive supranuclear palsy mimic versus typical progressive supranuclear palsy, OR: 8.8). The atypical multiple system atrophy cases more frequently had autonomic dysfunction within 3 years of symptom onset than the pathologically confirmed patients with Parkinson’s disease or progressive supranuclear palsy (Parkinson’s disease mimic versus typical Parkinson’s disease, OR: 4.7; progressive supranuclear palsy mimic versus typical progressive supranuclear palsy, OR: 2.7). Using all included clinical features and 21 early clinical features within 3 years of symptom onset, we developed decision tree algorithms with combinations of clinical pointers to differentiate clinically atypical cases of multiple system atrophy from Parkinson’s disease or progressive supranuclear palsy.

APA, Harvard, Vancouver, ISO, and other styles

24

Arena, Julieta E., Stephen D. Weigand, Jennifer L. Whitwell, Anhar Hassan, Scott D. Eggers, Günter U. Höglinger, Irene Litvan, and Keith A. Josephs. "Progressive supranuclear palsy: progression and survival." Journal of Neurology 263, no. 2 (December 24, 2015): 380–89. http://dx.doi.org/10.1007/s00415-015-7990-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Coakeley, Sarah, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Madeleine Harris, Christine Ghadery, Jinhee Kim, et al. "Positron emission tomography imaging of tau pathology in progressive supranuclear palsy." Journal of Cerebral Blood Flow & Metabolism 37, no. 9 (December 22, 2016): 3150–60. http://dx.doi.org/10.1177/0271678x16683695.

Full text

Abstract:

Progressive supranuclear palsy is a rare form of atypical Parkinsonism that differs neuropathologically from other parkinsonian disorders. While many parkinsonian disorders such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. [18F]AV-1451 (also known as [18F]-T807) is a positron emission tomography radiotracer that binds to paired helical filaments of tau in Alzheimer’s disease. We investigated whether [18F]AV-1451 could be used as biomarker for the diagnosis and disease progression monitoring in progressive supranuclear palsy. Six progressive supranuclear palsy, six Parkinson’s disease, and 10 age-matched healthy controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio from 60 to 90 min post-injection was calculated in each region of interest, using the cerebellar cortex as a reference region. No significant differences in standardized uptake value ratios were detected in our progressive supranuclear palsy group compared to the two control groups. [18F]AV-1451 may bind selectivity to the paired helical filaments in Alzheimer’s disease, which differ from the straight conformation of tau filaments in progressive supranuclear palsy.

APA, Harvard, Vancouver, ISO, and other styles

26

Brown, J., P. Lantos, M. Stratton, P. Roques, and M. Rossor. "Familial progressive supranuclear palsy." Journal of Neurology, Neurosurgery & Psychiatry 56, no. 5 (May 1, 1993): 473–76. http://dx.doi.org/10.1136/jnnp.56.5.473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

de Yébenes, J. G., J. L. Sarasa, S. E. Daniel, and A. J. Lees. "Familial progressive supranuclear palsy." Brain 118, no. 5 (1995): 1095–103. http://dx.doi.org/10.1093/brain/118.5.1095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Giaccone, G., F. Tagliavini, J. S. Street, B. Ghetti, and O. Bugiani. "PROGRESSIVE SUPRANUCLEAR PALSY (PSP)." Journal of Neuropathology and Experimental Neurology 46, no. 3 (May 1987): 387. http://dx.doi.org/10.1097/00005072-198705000-00173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Piccini, Paola. "Familial Progressive supranuclear Palsy." Archives of Neurology 58, no. 11 (November 1, 2001): 1846. http://dx.doi.org/10.1001/archneur.58.11.1846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Armstrong, Melissa J., Rudy J. Castellani, and Stephen G. Reich. "“Rapidly” Progressive Supranuclear Palsy." Movement Disorders Clinical Practice 1, no. 1 (April 2014): 70–72. http://dx.doi.org/10.1002/mdc3.12011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Dash, Sandip K. "Zolpidem in Progressive Supranuclear Palsy." Case Reports in Neurological Medicine 2013 (2013): 1–2. http://dx.doi.org/10.1155/2013/250865.

Full text

Abstract:

Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder, characterized by motor symptoms, postural instability, personality changes, and cognitive impairment. There is no effective treatment for this disorder. Reduced neurotransmission of GABA in the striatum and globus pallidus may contribute to the symptoms of motor and cognitive symptoms seen in PSP. Zolpidem is a GABA agonist of the benzodiazepine subreceptor BZ1. Here a nondiabetic, normotensive case of PSP is (Progressive Supranuclear Palsy) described, which showed improvement in swallowing, speech, and gaze paresis after zolpidem therapy and possible mechanism of actions are discussed. However, more trials are needed with large number of patients to confirm the effectiveness of zolpidem in progressive supranuclear palsy.

APA, Harvard, Vancouver, ISO, and other styles

32

Barsottini, Orlando Graziani Povoas, André Carvalho Felício, Camila Catherine Henriques de Aquino, and José Luiz Pedroso. "Progressive supranuclear palsy: new concepts." Arquivos de Neuro-Psiquiatria 68, no. 6 (December 2010): 938–46. http://dx.doi.org/10.1590/s0004-282x2010000600020.

Full text

Abstract:

Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia. PSP is defined neuropathologically by the accumulation of neurofibrillary tangles in the subthalamic nucleus, pallidum, red nucleus, substantia nigra, striatum, pontine tegmentum, oculomotor nucleus, medulla and dentate nucleus. Over the last decade many lines of investigations have helped refine PSP in many aspects and it is the purpose of this review to help neurologists identify PSP, to better understand its pathophysiology and to provide a more focused, symptom-based treatment approach.

APA, Harvard, Vancouver, ISO, and other styles

33

Ticku, Hemani, Neel Fotedar, Jorge Juncos, Stewart A. Factor, and Aasef G. Shaikh. "Pseudonystagmus in progressive supranuclear palsy." Journal of the Neurological Sciences 434 (March 2022): 120157. http://dx.doi.org/10.1016/j.jns.2022.120157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Levy, Richard. "Progressive supranuclear palsy: what's new?" Gériatrie et Psychologie Neuropsychiatrie du Viellissement 9, no. 2 (May 2011): 191–201. http://dx.doi.org/10.1684/pnv.2011.0271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Sandyk, Reuven. "Excessive Yawning Progressive Supranuclear Palsy." International Journal of Neuroscience 34, no. 1-2 (January 1987): 123–24. http://dx.doi.org/10.3109/00207458708985946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Daniele, Antonio, Elena Moro, and Anna Rita Bentivoglio. "Zolpidem in Progressive Supranuclear Palsy." New England Journal of Medicine 341, no. 7 (August 12, 1999): 543–44. http://dx.doi.org/10.1056/nejm199908123410721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Nygaard, T. G., R. C. Duvoisin, M. Manocha, and S. Chokroverty. "Seizures in progressive supranuclear palsy." Neurology 39, no. 1 (January 1, 1989): 138. http://dx.doi.org/10.1212/wnl.39.1.138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Masucci, E. F., and J. F. Kurtzke. "Tremor in progressive supranuclear palsy." Acta Neurologica Scandinavica 80, no. 4 (October 1989): 296–300. http://dx.doi.org/10.1111/j.1600-0404.1989.tb03882.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kaas, Bonnie, Argye E. Hillis, and Alexander Pantelyat. "Progressive supranuclear palsy and pawpaw." Neurology: Clinical Practice 10, no. 2 (August 20, 2019): e17-e18. http://dx.doi.org/10.1212/cpj.0000000000000704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Apetauerova, Diana, Stephanie A. Scala, Robert W. Hamill, David K. Simon, Subash Pathak, Robin Ruthazer, David G. Standaert, and Talene A. Yacoubian. "CoQ10 in progressive supranuclear palsy." Neurology - Neuroimmunology Neuroinflammation 3, no. 5 (August 2, 2016): e266. http://dx.doi.org/10.1212/nxi.0000000000000266.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Uttl, B., P. Santacruz, I. Litvan, and J. Grafman. "Caregiving in progressive supranuclear palsy." Neurology 51, no. 5 (November 1, 1998): 1303–9. http://dx.doi.org/10.1212/wnl.51.5.1303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Weiner, W. J., A. Minagar, and L. M. Shulman. "Pramipexole in progressive supranuclear palsy." Neurology 52, no. 4 (March 1, 1999): 873. http://dx.doi.org/10.1212/wnl.52.4.873.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Schlesinger, Ilana, Ana Klesier, and David Yarnitsky. "Pain in Progressive Supranuclear Palsy." Clinical Neuropharmacology 32, no. 3 (May 2009): 163–64. http://dx.doi.org/10.1097/wnf.0b013e31818a383c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Sandyk, R., and S. R. Snider. "Naloxone in Progressive Supranuclear Palsy." Clinical Neuropharmacology 8, no. 2 (June 1985): 198. http://dx.doi.org/10.1097/00002826-198506000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Im, Sun Young, Young Eun Kim, and Yun Joong Kim. "Genetics of Progressive Supranuclear Palsy." Journal of Movement Disorders 8, no. 3 (September 10, 2015): 122–29. http://dx.doi.org/10.14802/jmd.15033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Barclay, C. L., and A. E. Lang. "Dystonia in progressive supranuclear palsy." Journal of Neurology, Neurosurgery & Psychiatry 62, no. 4 (April 1, 1997): 352–56. http://dx.doi.org/10.1136/jnnp.62.4.352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rabadia, Soniya V., Irene Litvan, Jorge Juncos, Yvette Bordelon, David E. Riley, David Standaert, Stephen G. Reich, et al. "Hypertension and progressive supranuclear palsy." Parkinsonism & Related Disorders 66 (September 2019): 166–70. http://dx.doi.org/10.1016/j.parkreldis.2019.07.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Vaswani, Pavan A., and Abby L. Olsen. "Immunotherapy in progressive supranuclear palsy." Current Opinion in Neurology 33, no. 4 (June 9, 2020): 527–33. http://dx.doi.org/10.1097/wco.0000000000000836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Koros, Christos, and Maria Stamelou. "Interventions in progressive supranuclear palsy." Parkinsonism & Related Disorders 22 (January 2016): S93—S95. http://dx.doi.org/10.1016/j.parkreldis.2015.09.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Muinjonov, Bakhrom, and Elvina Giyazitdinova. "Hyposmia in progressive supranuclear palsy." Parkinsonism & Related Disorders 22 (January 2016): e120. http://dx.doi.org/10.1016/j.parkreldis.2015.10.280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!